BTIG Research Boosts Genmab A/S (NASDAQ:GMAB) Price Target to $47.00

Genmab A/S (NASDAQ:GMAB) had its target price lifted by BTIG Research from $46.00 to $47.00 in a research note published on Thursday morning, Benzinga reports. BTIG Research currently has a buy rating on the stock.

Other research analysts have also issued research reports about the stock. Morgan Stanley restated an underweight rating on shares of Genmab A/S in a research report on Tuesday, March 26th. HC Wainwright restated a buy rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday. Finally, Truist Financial upped their target price on Genmab A/S from $50.00 to $53.00 and gave the company a buy rating in a research report on Tuesday, June 4th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Hold and an average price target of $49.50.

Genmab A/S Trading Down 1.8 %

NASDAQ:GMAB opened at $25.13 on Thursday. The stock has a 50 day simple moving average of $27.96 and a 200 day simple moving average of $29.11. The stock has a market cap of $16.62 billion, a P/E ratio of 20.94, a PEG ratio of 0.93 and a beta of 0.99. Genmab A/S has a 1-year low of $24.94 and a 1-year high of $42.72.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. The company had revenue of $603.30 million during the quarter, compared to the consensus estimate of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. As a group, sell-side analysts forecast that Genmab A/S will post 1.11 EPS for the current year.

Institutional Trading of Genmab A/S

Several large investors have recently bought and sold shares of the business. NewEdge Wealth LLC lifted its holdings in shares of Genmab A/S by 50.7% in the fourth quarter. NewEdge Wealth LLC now owns 119,989 shares of the company’s stock worth $3,820,000 after acquiring an additional 40,382 shares during the last quarter. Harding Loevner LP lifted its stake in Genmab A/S by 2.7% in the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after purchasing an additional 85,665 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Genmab A/S by 350.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock valued at $154,000 after buying an additional 3,770 shares in the last quarter. Northern Trust Corp grew its stake in shares of Genmab A/S by 83.3% during the third quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock worth $19,717,000 after buying an additional 254,042 shares during the last quarter. Finally, Natixis Advisors L.P. increased its holdings in shares of Genmab A/S by 38.9% during the third quarter. Natixis Advisors L.P. now owns 228,897 shares of the company’s stock worth $8,073,000 after buying an additional 64,085 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.